Show simple item record

dc.contributor.authorRossiter, S.
dc.contributor.authorSmith, C.L.
dc.contributor.authorMalaki, M.
dc.contributor.authorNandi, M.
dc.contributor.authorGill, H.
dc.contributor.authorLeiper, J.M.
dc.contributor.authorVallance, P.
dc.contributor.authorSelwood, D.L.
dc.identifier.citationRossiter , S , Smith , C L , Malaki , M , Nandi , M , Gill , H , Leiper , J M , Vallance , P & Selwood , D L 2005 , ' Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase ' , Journal of Medicinal Chemistry , vol. 48 , no. 14 , pp. 4670-4678 .
dc.identifier.otherPURE: 183643
dc.identifier.otherPURE UUID: 37e08a2b-fdd6-4d0f-8e94-598f97801cf3
dc.identifier.otherdspace: 2299/2619
dc.identifier.otherScopus: 22244439271
dc.descriptionOriginal article can be found at: Copyright American Chemical Society DOI: 10.1021/jm050187a [Full text of this article is not available in the UHRA]
dc.description.abstractThe enzyme DDAH metabolizes methylarginines that are inhibitors of nitric oxide synthase (NOS). Substrate-based inhibitors of mammalian DDAH have been synthesized, with optimization to give selective inhibition of DDAH with no significant direct effect on NOSs. These are the first examples of reversible DDAH inhibitors with significant activity and selectivity. In vivo administration increases plasma ADMA levels, giving proof of concept that these inhibitors can be used to probe the physiological effects of DDAH inhibition, with potential for pharmaceutical use of DDAH inhibitors in diseases where excess NO production is implicated.en
dc.relation.ispartofJournal of Medicinal Chemistry
dc.titleSelective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolaseen
dc.contributor.institutionDepartment of Pharmacy
dc.description.statusPeer reviewed
rioxxterms.typeJournal Article/Review

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record